Oil prices hold sharp losses with focus on secondary India tariffs
On Friday, Canaccord Genuity analysts adjusted their outlook for Repligen Corporation (NASDAQ:RGEN), increasing the 12-month price target to $170 from the previous $165 while maintaining a Hold rating on the stock. The revision reflects a modest enhancement in the company’s margin expansion as projected in Canaccord’s 10-year discounted cash flow (DCF) model. The stock, currently trading at $162.67 with a market capitalization of $9.1 billion, has shown strong momentum with a 10.7% gain over the past week. According to InvestingPro analysis, Repligen appears to be trading above its Fair Value.
Repligen, which specializes in bioprocessing technologies, shared its fourth-quarter 2024 results on Thursday, February 20, 2025, before the market opened. The financial performance met both Canaccord’s estimates and the FactSet consensus. The management’s commentary on the company’s orders and the positive initial outlook for 2025 were particularly noteworthy. Sales and orders from critical end markets, including Contract Development and Manufacturing Organizations (CDMOs) and pharmaceutical companies, are reportedly progressing well. InvestingPro data shows the company maintains a "GOOD" financial health score of 2.52, with particularly strong cash flow metrics.
The company’s various franchises are also expected to experience solid growth throughout 2025. Repligen’s initial guidance for the year aligns with the general expectations of Wall Street analysts. Canaccord Genuity suggests that there could be potential for the company to outperform this guidance if the bioprocessing industry recovers more swiftly than anticipated or if Repligen’s unique market position leads to significant new business opportunities.
Despite the increased price target, Canaccord Genuity’s assessment indicates that the current share price does not offer significant upside potential based on their valuation. The firm’s stance is influenced by the company’s solid initial outlook for the year and the potential for growth in key market segments.
In other recent news, Repligen Corporation reported its fourth-quarter results, revealing an earnings per share (EPS) of $0.44, surpassing analyst expectations by $0.03. The company recorded revenue of $168 million, slightly above the anticipated $167.67 million. Repligen has also provided an optimistic outlook for fiscal year 2025, projecting revenue between $685 million and $710 million, which exceeds the consensus estimate at the upper end. KeyBanc Capital Markets maintained its Overweight rating on Repligen, setting a price target of $220, following the company’s strong performance and future growth potential. Jefferies, on the other hand, raised its price target for Repligen to $165 while retaining a Hold rating, acknowledging the company’s solid fourth-quarter results and slightly ahead 2025 guidance. Repligen’s product offerings, particularly in ATF filtration, are expected to drive growth, with the company also seeing increased orders for Contract Development and Manufacturing Organizations (CDMOs) and capital equipment. The company recently acquired Tantti Laboratory Inc. and launched innovative products like the AVIPure® dsRNA resin, contributing to its growth trajectory. As Repligen continues to expand its market presence, the company’s strategic initiatives and financial guidance suggest a promising outlook for the coming year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.